Loading...
Opportunity Identification: A Case Study on Commercializing Biomedical Research | Seminar Series
Biomedical Research Building Auditorium, Rm. 105
2109 Adelbert Road Rm. 105, Cleveland, OH 44106, United States
View Map
93
Registered
Registration
Registration is now closed (this event already took place).
Details
Lewis has over 20 years of executive experience and a history of success in the pharmaceutical and finance industries in both the US and internationally. He co-founded Aegerion Pharmaceuticals, a biopharmaceutical company, and served as its President and COO. In 2012, Lewis joined Insmed, a global biopharmaceutical company that develops and brings to market therapies for patients with serious and rare diseases, where he serves as CEO and Chairman.
Will will be joined by Chris Bailey-Kellogg, executive director of Computational Biology, and Karl Griswold, executive director of Biologics Research, two Dartmouth College faculty members who recently commercialized their research and had their company acquired by Insmed. Engage in discussion and hear the acquisition story of Stealth Biologics, LLC, from research to patient impact through commercialization.
In June of 2020, Will joined us to share his career journey, experience in entrepreneurship, and how the COVID-19 crisis impacts the pharmaceutical industry and the advancement of new treatments in medicine. You can watch his previous talk here.
This session will be offered in-person in the Biomedical Research Building Room 105 and via zoom.
The next session in the series will be held Oct. 7 at 4 p.m.
Where
Biomedical Research Building Auditorium, Rm. 105
2109 Adelbert Road Rm. 105, Cleveland, OH 44106, United States
Speakers
Will Lewis
Chairman & CEO
Insmed
https://www.linkedin.com/in/will-lewis-aa89161a8/
Will joined Insmed in 2012 as President and Chief Executive Officer and as a member of the board of directors. He became chair of the board of directors in November 2018. Will is the former Co-Founder, President, and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), and previously spent more than 10 years working in investment banking in the U.S. and Europe. He also previously worked for the U.S. government. Will holds a Bachelor of Arts degree cum laude from Oberlin College as well as a Master of Business Administration and a Juris Doctor with Honors from Case Western Reserve University. Will serves as the chair of the board of trustees of BioNJ, the life sciences association for New Jersey. Will is a member of the board of trustees of Case Western Reserve University as well as a member of the board of the Helix Acquisition Corp.
Chris Bailey-Kellogg
Excutive Director of Computational Biology
Insmed
https://www.linkedin.com/in/chris-bailey-kellogg-464b9082/
Chris is part of the Research department based at RDL-NH, and reports to Walter Perkins, Chief Technology Officer. Chris earned his PhD in Computer and Information Science from Ohio State University and his Bachelor of Science/Master of Science in Electrical Engineering and Computer Science from MIT.
Chris is part of the team working on Deimmunized by Design, a proprietary protein deimmunization platform. This leading-edge technology uses artificial intelligence to deimmunize therapeutic proteins, which would otherwise be made ineffective by our body’s immune system. Chris is based in New Hampshire at our RDL-NH facility.
Karl Griswold
Executive Director of Biologics Research
Insmed
https://www.linkedin.com/in/karl-griswold-97a43144/
Karl is part of the Research department based at RDL-NH, and reports to Walter Perkins, Chief Technology Officer. Karl earned his PhD in Chemistry from the University of Texas at Austin and his Bachelor of Science in Chemistry from Texas State University.
Karl is part of the team working on Deimmunized by Design, a proprietary protein deimmunization platform. This leading-edge technology uses artificial intelligence to deimmunize therapeutic proteins, which would otherwise be made ineffective by our body’s immune system.